Clean Harbors vs. Waste Management: Which Industrials Stock Is a Better Buy in 2026?

The article contrasts Clean Harbors (CLH) and Waste Management (WM) for 2026, citing FY2025 revenue of nearly $6.0B (CLH, ~+2.4%) and $25.2B (WM, +14.2%). Valuation is lower for WM with forward P/E of 28.2x vs CLH’s 33.8x, and WM also shows higher FY2025 free cash flow (~$2.8B vs ~$438.2M) alongside dividend/buyback support. Key risks differ: CLH faces EPA scrutiny including a 2026 settlement over Safety-Kleen and exposure to “forever chemicals” regulation plus higher fuel costs, while WM is integrating Stericycle and remains exposed to recycling commodity volatility.

Analysis

The market mechanism here is less "who wins waste" than "who can monetize regulatory complexity without leaking margin." WM is the higher-quality compounding vehicle if management keeps Stericycle integration on schedule; the healthcare waste mix should be stickier than municipal trash and can lift revenue per stop, but any billing-system stumble would hit reported cash conversion fast because this business is valued on consistency. CLH has the cleaner regulatory narrative, yet the thesis is more fragile than it looks: hazardous disposal is capacity-constrained, but fuel, remediation, and permit-compliance costs rise with the same tightening regime that expands demand.

Second-order, the biggest beneficiary of a pullback in WM multiples could be RSG, which offers similar landfill/network economics without the same integration overhang and typically gets less credit for disciplined capital allocation. On the CLH side, stricter PFAS/industrial wastewater enforcement is a multi-year tailwind, but it also expands the addressable market for niche private operators and environmental engineering firms, so pricing power may be shared rather than captured entirely by one name.

Contrarian view: investors may be overpaying for the "regulation = CLH upside" story and underestimating how much of that upside is offset by energy intensity and liability drag. In contrast, WM’s lower earnings multiple matters because the real risk is operational, not demand-related; if the Stericycle cross-sell works, the stock can rerate without heroic volume assumptions. Near term, there is no obvious catalyst to force a clean relative move; the next inflection is quarterly integration commentary and any change in EPA enforcement cadence over the next 1-3 months, with the structural story playing out over 6-18 months.

Key Decisions for Investors

• Prefer WM over CLH on a 6-18 month horizon; if buying now, use WM as the core defensive compounder and require evidence of Stericycle margin accretion before adding size.
• Set a watchlist trigger on WM: if integration commentary implies no gross-margin or free-cash-flow drag over the next two quarters, add on any 5-7% pullback; if leverage stays elevated or synergies slip, reassess.
• Relative-value idea: long RSG / short WM into any valuation gap if WM trades at a premium despite integration risk; the pair benefits if capital markets start rewarding execution certainty over headline growth.
• Avoid chasing CLH on the assumption that tighter EPA rules are an automatic earnings tailwind; wait for proof that fuel pass-through and remediation costs are not offsetting incremental pricing power.
• Falsifier for the WM-long thesis: any downward revision to Stericycle synergies, FCF conversion below expectations, or leverage not trending lower by the next two reporting cycles.